Vericel Corp - Company Profile

Powered by

All the data and insights you need on Vericel Corp in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Vericel Corp Strategy Report

  • Understand Vericel Corp position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Vericel Corp: Overview

Select Item

Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn care domain. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. It also holds an exclusive license for NexoBrid in North America for the treatment of severe thermal burns. The company has manufacturing facility in Cambridge, Massachusetts and sells its products to sports medicine orthopedic surgeons and specialized burn centers through cell therapy specialists in the US. Vericel is headquartered in Cambridge, Massachusetts, the US.

 Gain a 360-degree view of Vericel Corp and make more informed decisions for your business Gain a 360-degree view of Vericel Corp and make more informed decisions for your business Find out more
Headquarters United States of America
Address 64 Sidney St, Cambridge, Massachusetts, 02139-4170
Website vcel.com
Telephone 1 734 9305555
No of Employees 314
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange VCEL (NASD)
Revenue (2022) $197.5M 20.2% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 81% (2022 vs 2021)
Market Cap* $2.2B
Net Profit Margin (2022) XYZ 84.2% (2022 vs 2021)
* As of and is in US$
View Vericel Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Vericel Corp premium industry data and analytics

14+

Clinical Trials

Determine Vericel Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

6

Catalyst Calendar

Proactively evaluate Vericel Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

4

Pipeline Drugs

Identify which of Vericel Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

4

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Sales & Consensus Forecasts

Understand the current and future drug revenue for Vericel Corp and assess market opportunity for new entrants with patient population 8-year forecasts.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Marketed Drugs

Understand Vericel Corp’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Vericel Corp’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Cultured Epidermal Autograft MACI
Autologous Cultured Chondrocytes on Porcine Collagen Membrane – MACI NexoBrid
Preapproval Product: Epicel
XYZ
XYZ
XYZ
Understand Vericel Corp portfolio and identify potential areas for collaboration Understand Vericel Corp portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Vericel Corp Stryker Corp Zimmer Biomet Holdings Inc Anika Therapeutics Inc Aesculap Biologics LLC
Headquarters United States of America United States of America United States of America United States of America United States of America
City Cambridge Kalamazoo Warsaw Bedford Breinigsville
State/Province Massachusetts Michigan Indiana Massachusetts Pennsylvania
No. of Employees 314 52,000 18,000 345 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Robert L. Zerbe, M.D. Chairman Executive Board 2012 71
Dominick C. Colangelo Director; Chief Executive Officer; President Executive Board 2013 58
Joe Mara Chief Financial Officer Senior Management 2021 47
Michael Halpin Chief Operating Officer Senior Management 2017 60
Jonathan Hopper Chief Medical Officer Senior Management 2018 59
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Vericel Corp key executives to enhance your sales strategy Gain insight into Vericel Corp key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward